1e
19
1
49
2
2
18
1b
1d
18
2d
44
1d
2 29
1d
25
Lin Zhang, M.D.
78
44
Harry Fields Research Professor
7
70
Department: Obstetrics and Gynecology
4
1
b
1d
46
Contact information
5b
4
3
3
1d
5b
University of Pennsylvania School of Medicine
3b 421 Curie Blvd, Biomedical Research Building II/III
24 Lab: 1233~1237; Office: 1207
3e linzhang@mail.med.upenn.edu
Philadelphia, PA 19104
26
3b 421 Curie Blvd, Biomedical Research Building II/III
24 Lab: 1233~1237; Office: 1207
3e linzhang@mail.med.upenn.edu
Philadelphia, PA 19104
2e
Office: 215-573-4780
32 Fax: 215-573-7627
32 Lab: 215-573-7947
18
f
32 Fax: 215-573-7627
32 Lab: 215-573-7947
18
18
Publications
23 a
3
2
29
23 a
Links
b3 Search PubMed for articles
79 Google Scholar
84 Selected Publications
6d Functional Cancer Genome (FCG) data portal
c
4
a
3
3
3
8a
Permanent linkb3 Search PubMed for articles
79 Google Scholar
84 Selected Publications
6d Functional Cancer Genome (FCG) data portal
c
2 29
21
1e
1d
24
5e
8
49 Noncoding RNAs in epigenetic regulation and DNA damage response.
25a We were one of the first laboratories to comprehensively characterize long noncoding RNA dysregulation in a large sample cohort. Through our multidimensional genomic analysis, we have made notable discoveries linking long noncoding RNA alterations to somatic copy number changes, promoter hypermethylation, and cancer risk-associated single nucleotide polymorphisms (SNPs). Using a genomic-guided genetic screening approach, our laboratory has identified several cancer-associated noncoding RNAs and extensively investigated their functions in epigenetic regulation and the DNA damage response.
8
54 Immunotherapy and targeted therapy for ovarian and breast cancer treatment.
2d3 Our early and ongoing research is dedicated to characterizing the antitumor immune response and developing innovative immunotherapy and targeted therapy strategies for cancer patients. Recently, utilizing a computational biology approach, our laboratory has conducted functional characterization of genomic alterations in druggable genes, including epigenetic regulatory genes, across various cancer types. This comprehensive analysis has led to the identification of novel therapeutic targets and the formulation of effective drug combination strategies. Notably, we have provided robust rationale for the "treatment-induced BRCAness" strategy in the treatment of both intrinsic and acquired HR-proficient cancers.
8
3b Functional characterization of the cancer genomes.
2d8 By employing a combination of multiple computational algorithms, our laboratory has developed a systems biology approach to integrate multi-dimensional and large-scale genomic profiles. This innovative approach has led to the creation of a publicly accessible database known as the Functional Cancer Genome data portal (FCG data portal). With the aim of aiding researchers in the analysis and visualization of cancer genomic data, we have released multiple genomic data sets through our FCG data portal, including the Cancer LncRNome Atlas (TCLA) and the Cancer Genetic Ancestry Atlas (TCGAA). These resources provide valuable tools for the scientific community to explore and unravel the complexities of cancer genomics.
26 29
27
Description of Research Expertise
7c6 Our research has been focused on unraveling the molecular mechanisms underlying ovarian and breast cancers and developing innovative immunotherapies and targeted therapies for these diseases. Our early and ongoing research has focused on investigating the antitumor immune response and developing immunotherapy strategies specifically for ovarian cancer. We provided robust clinical evidence supporting the concept of immune surveillance in ovarian cancer (New England Journal of Medicine, 2003). We demonstrated that the tumor microenvironment promotes immune tolerance and angiogenesis through chemokines and regulatory T cells (Nature, 2011). Currently, our research aims to unravel the contribution of recurrent genomic alterations in both protein-coding and non-coding regions to tumorigenesis, with a specific emphasis on identifying therapeutic targets and combination strategies for treating ovarian and breast cancer. To achieve this, we have developed a novel computational approach that integrates large-scale genomic, functionomic, and pharmcologomic profiles. Our efforts have resulted in the creation of the Functional Cancer Genome data portal (FCG, http://fcgportal.org/home/), to functionally annotate cancer genomes (Cancer Cell, 2014, 2015, 2018; Nature Structural and Molecular Biology, 2016; Nature Cancer, 2021). Our research has revealed that genes encoding histone modification enzymes exhibit high-frequency recurrent genomic alterations in cancers, highlighting their potential as clinically actionable drug targets (Nature Communications, 2019; Cell Reports, 2020, 2022). Most recently, we have demonstrated the efficacy and tolerability of a combination treatment strategy known as "treatment-induced BRCAness" in both primary and acquired HR-proficient tumors (Science Translational Medicine, 2017). This innovative combination approach is currently undergoing evaluation in a phase 2 clinical trial and has shown promising treatment responses.8
49 Noncoding RNAs in epigenetic regulation and DNA damage response.
25a We were one of the first laboratories to comprehensively characterize long noncoding RNA dysregulation in a large sample cohort. Through our multidimensional genomic analysis, we have made notable discoveries linking long noncoding RNA alterations to somatic copy number changes, promoter hypermethylation, and cancer risk-associated single nucleotide polymorphisms (SNPs). Using a genomic-guided genetic screening approach, our laboratory has identified several cancer-associated noncoding RNAs and extensively investigated their functions in epigenetic regulation and the DNA damage response.
8
54 Immunotherapy and targeted therapy for ovarian and breast cancer treatment.
2d3 Our early and ongoing research is dedicated to characterizing the antitumor immune response and developing innovative immunotherapy and targeted therapy strategies for cancer patients. Recently, utilizing a computational biology approach, our laboratory has conducted functional characterization of genomic alterations in druggable genes, including epigenetic regulatory genes, across various cancer types. This comprehensive analysis has led to the identification of novel therapeutic targets and the formulation of effective drug combination strategies. Notably, we have provided robust rationale for the "treatment-induced BRCAness" strategy in the treatment of both intrinsic and acquired HR-proficient cancers.
8
3b Functional characterization of the cancer genomes.
2d8 By employing a combination of multiple computational algorithms, our laboratory has developed a systems biology approach to integrate multi-dimensional and large-scale genomic profiles. This innovative approach has led to the creation of a publicly accessible database known as the Functional Cancer Genome data portal (FCG data portal). With the aim of aiding researchers in the analysis and visualization of cancer genomic data, we have released multiple genomic data sets through our FCG data portal, including the Cancer LncRNome Atlas (TCLA) and the Cancer Genetic Ancestry Atlas (TCGAA). These resources provide valuable tools for the scientific community to explore and unravel the complexities of cancer genomics.
26 29
23
1c4 Hu X, Feng Y, Zhang D, Zhao SD, Hu Z, Greshock J, Zhang Y, Yang L, Zhong X, Wang L-P, Jean S, Li C, Huang Q, Katsaros D, Montone KT, Tanyi JL, Lu Y, Boyd J, Nathanson KL, Li H, Mills GB, Zhang L: A Functional Genomic Approach Identifies FAL1 as an Oncogenic Long Noncoding RNA that Associates with BMI1 and Represses p21 Expression in Cancer. Cancer Cell 26(3): 344-57, Sep 2014.
1c4 Yan X, Hu Z, Feng Yi, Hu X, Yuan J, Zhao SD, Zhang Y, Yang L, Shan W, He Q, Fan L, Kandalaft LE, Tanyi JL, Li C, Yuan C-X, Zhang D, Yuan H, Hua K, Lu Y, Katsaros D, Huang Q, Montone K, Fan Y, Coukos G, Boyd J, Sood AK, Rebbeck T, Mills GB, Dang CV, Zhang L: Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers. Cancer Cell 28(4): 529-40, Oct 2015.
15b Zhang Y, He Q, HU Z, Feng Y, Fan L, Tang Z, Yuan J, Shan W, Li C, Hu X, Tanyi JL, Fan Y, Huang Q, Montone K, Dang CV, Zhang L: Long noncoding RNA LINP1 regulates repair of DNA double-strand breaks in triple-negative breast cancer. Nat Struct Mol Biol 23(6):522-30, Apr 2016.
159 Yang L, Zhang Y, Shan W, Hu Z, Yuan J, Pi J, Wang Y, Fan L, Tang Z, Li C, Hu X, Tanyi JL, Fan Y, Huang Q, Montone K, Dang CV, Zhang L: Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition. Sci Transl Med 26:9(400), Jul 2017.
18c Yuan J, Hu Z, Mahal B, Zhao S, Kensler K, Pi J, Hu X, Wang Y, Jiang J, Zhang Y, Li C, Zhong X, Montone K, Guan G, Tanyi J, Fan Y, Xu X, Long M, Morgan M, Zhang Y, Zhang R, Sood A, Rebbeck T, Dang C, Zhang L: Integrated analysis of genetic ancestry and genomic alterations across cancers. Cancer Cell 34(4):549-560.e9, 2018.
21b Zhongyi Hu, Junzhi Zhou, Junjie Jiang, Jiao Yuan, Youyou Zhang, Xuepeng Wei, Nicki Loo, Yueying Wang, Yutian Pan, Tianli Zhang, Xiaomin Zhong, Meixiao Long, Kathleen Montone, Janos Tanyi, Yi Fan, Tian-Li Wang, Ie-Ming Shih, Xiaowen Hu, Lin Zhang: Genomic characterization of genes encoding histone acetylation modulator proteins identifies therapeutic targets for cancer treatment. Nature Communications Page: Feb 13;10(1):733. doi: 10.1038/s41467-019-08554-x. 2019.
19a Shan W, Yuan J, Hu J, Jiang J, Wang Y, Loo N, Fan L, Tang Z, Zhang T, Xu M, Pan Y, Lu J, Long M, Tanyi LJ, Montone KT, Fan Y, Hu X, Zhang Y, Zhang L.: Systematic characterization of recurrent genomic alterations in cyclin-dependent kinases reveals potential therapeutic strategies for cancer treatment. Cell Reports 32 (2), 107884, 2020.
166 Hu Z, Yuan J, Long M, Jiang J, Zhang Y, Zhang T, Xu M, Fan Y, Tanyi JL, Montone KT, Tavana O, Chan HM, Hu X, Vonderheide RH, Zhang L: The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets. Nat Cancer 2(12):1406-1422, Dec 2021.
12c Jiang J, Yuan J, Hu Z, Zhang Y, Zhang T, Xu M, Long M, Fan Y, Tanyi JL, Montone KT, Tavana O, Vonderheide RH, Chan HM, Hu X, Zhang L.: Systematic illumination of druggable genes in cancer genomes. Cell Rep 38: 110400, Feb 2022.
2c
7
1d
1f
Selected Publications
163 Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman M N, Rubin SC, Coukos G: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. New England Journal of Medicine 348(3): 203-13, Jan 2003.1c4 Hu X, Feng Y, Zhang D, Zhao SD, Hu Z, Greshock J, Zhang Y, Yang L, Zhong X, Wang L-P, Jean S, Li C, Huang Q, Katsaros D, Montone KT, Tanyi JL, Lu Y, Boyd J, Nathanson KL, Li H, Mills GB, Zhang L: A Functional Genomic Approach Identifies FAL1 as an Oncogenic Long Noncoding RNA that Associates with BMI1 and Represses p21 Expression in Cancer. Cancer Cell 26(3): 344-57, Sep 2014.
1c4 Yan X, Hu Z, Feng Yi, Hu X, Yuan J, Zhao SD, Zhang Y, Yang L, Shan W, He Q, Fan L, Kandalaft LE, Tanyi JL, Li C, Yuan C-X, Zhang D, Yuan H, Hua K, Lu Y, Katsaros D, Huang Q, Montone K, Fan Y, Coukos G, Boyd J, Sood AK, Rebbeck T, Mills GB, Dang CV, Zhang L: Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers. Cancer Cell 28(4): 529-40, Oct 2015.
15b Zhang Y, He Q, HU Z, Feng Y, Fan L, Tang Z, Yuan J, Shan W, Li C, Hu X, Tanyi JL, Fan Y, Huang Q, Montone K, Dang CV, Zhang L: Long noncoding RNA LINP1 regulates repair of DNA double-strand breaks in triple-negative breast cancer. Nat Struct Mol Biol 23(6):522-30, Apr 2016.
159 Yang L, Zhang Y, Shan W, Hu Z, Yuan J, Pi J, Wang Y, Fan L, Tang Z, Li C, Hu X, Tanyi JL, Fan Y, Huang Q, Montone K, Dang CV, Zhang L: Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition. Sci Transl Med 26:9(400), Jul 2017.
18c Yuan J, Hu Z, Mahal B, Zhao S, Kensler K, Pi J, Hu X, Wang Y, Jiang J, Zhang Y, Li C, Zhong X, Montone K, Guan G, Tanyi J, Fan Y, Xu X, Long M, Morgan M, Zhang Y, Zhang R, Sood A, Rebbeck T, Dang C, Zhang L: Integrated analysis of genetic ancestry and genomic alterations across cancers. Cancer Cell 34(4):549-560.e9, 2018.
21b Zhongyi Hu, Junzhi Zhou, Junjie Jiang, Jiao Yuan, Youyou Zhang, Xuepeng Wei, Nicki Loo, Yueying Wang, Yutian Pan, Tianli Zhang, Xiaomin Zhong, Meixiao Long, Kathleen Montone, Janos Tanyi, Yi Fan, Tian-Li Wang, Ie-Ming Shih, Xiaowen Hu, Lin Zhang: Genomic characterization of genes encoding histone acetylation modulator proteins identifies therapeutic targets for cancer treatment. Nature Communications Page: Feb 13;10(1):733. doi: 10.1038/s41467-019-08554-x. 2019.
19a Shan W, Yuan J, Hu J, Jiang J, Wang Y, Loo N, Fan L, Tang Z, Zhang T, Xu M, Pan Y, Lu J, Long M, Tanyi LJ, Montone KT, Fan Y, Hu X, Zhang Y, Zhang L.: Systematic characterization of recurrent genomic alterations in cyclin-dependent kinases reveals potential therapeutic strategies for cancer treatment. Cell Reports 32 (2), 107884, 2020.
166 Hu Z, Yuan J, Long M, Jiang J, Zhang Y, Zhang T, Xu M, Fan Y, Tanyi JL, Montone KT, Tavana O, Chan HM, Hu X, Vonderheide RH, Zhang L: The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets. Nat Cancer 2(12):1406-1422, Dec 2021.
12c Jiang J, Yuan J, Hu Z, Zhang Y, Zhang T, Xu M, Long M, Fan Y, Tanyi JL, Montone KT, Tavana O, Vonderheide RH, Chan HM, Hu X, Zhang L.: Systematic illumination of druggable genes in cancer genomes. Cell Rep 38: 110400, Feb 2022.
2c